WO2021169744A1 - 一种荧光碳量子点及其制备方法和在制备抗肿瘤药物增敏剂中的用途 - Google Patents
一种荧光碳量子点及其制备方法和在制备抗肿瘤药物增敏剂中的用途 Download PDFInfo
- Publication number
- WO2021169744A1 WO2021169744A1 PCT/CN2021/074781 CN2021074781W WO2021169744A1 WO 2021169744 A1 WO2021169744 A1 WO 2021169744A1 CN 2021074781 W CN2021074781 W CN 2021074781W WO 2021169744 A1 WO2021169744 A1 WO 2021169744A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- sugar
- ecnds
- preparation
- carbon quantum
- Prior art date
Links
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 25
- 235000000346 sugar Nutrition 0.000 claims abstract description 125
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 239000003921 oil Substances 0.000 claims description 51
- 235000019198 oils Nutrition 0.000 claims description 51
- 235000005687 corn oil Nutrition 0.000 claims description 24
- 239000002285 corn oil Substances 0.000 claims description 24
- 239000011435 rock Substances 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 18
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 18
- 229960003787 sorafenib Drugs 0.000 claims description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 229960004964 temozolomide Drugs 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 12
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 12
- 235000019482 Palm oil Nutrition 0.000 claims description 12
- 235000019483 Peanut oil Nutrition 0.000 claims description 12
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 12
- 235000019498 Walnut oil Nutrition 0.000 claims description 12
- 229940116229 borneol Drugs 0.000 claims description 12
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 12
- 239000010495 camellia oil Substances 0.000 claims description 12
- 239000000828 canola oil Substances 0.000 claims description 12
- 235000019519 canola oil Nutrition 0.000 claims description 12
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 12
- 239000008169 grapeseed oil Substances 0.000 claims description 12
- 239000010460 hemp oil Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000004006 olive oil Substances 0.000 claims description 12
- 235000008390 olive oil Nutrition 0.000 claims description 12
- 239000002540 palm oil Substances 0.000 claims description 12
- 239000000312 peanut oil Substances 0.000 claims description 12
- 239000008159 sesame oil Substances 0.000 claims description 12
- 235000011803 sesame oil Nutrition 0.000 claims description 12
- 239000003549 soybean oil Substances 0.000 claims description 12
- 235000012424 soybean oil Nutrition 0.000 claims description 12
- 239000008170 walnut oil Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 208000032612 Glial tumor Diseases 0.000 claims description 10
- 206010018338 Glioma Diseases 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 5
- 229940044683 chemotherapy drug Drugs 0.000 claims description 5
- 239000008157 edible vegetable oil Substances 0.000 claims description 5
- 235000021552 granulated sugar Nutrition 0.000 claims description 5
- 238000005292 vacuum distillation Methods 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 229910014033 C-OH Inorganic materials 0.000 claims description 3
- 229910014570 C—OH Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000011034 membrane dialysis Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000002096 quantum dot Substances 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 238000000703 high-speed centrifugation Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 238000011503 in vivo imaging Methods 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 238000000554 physical therapy Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- DTSCLFDGIVWOGR-UHFFFAOYSA-N 1,3-dimethyl-5h-pyrido[2,3]pyrrolo[2,4-b]pyrimidine-2,4-dione Chemical compound C12=NC=CC=C2NC2=C1N(C)C(=O)N(C)C2=O DTSCLFDGIVWOGR-UHFFFAOYSA-N 0.000 claims 1
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- JXBAVRIYDKLCOE-UHFFFAOYSA-N [C].[P] Chemical compound [C].[P] JXBAVRIYDKLCOE-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 235000020238 sunflower seed Nutrition 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 40
- 238000011282 treatment Methods 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 23
- 239000008103 glucose Substances 0.000 abstract description 23
- 230000035755 proliferation Effects 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 10
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 230000004190 glucose uptake Effects 0.000 abstract description 4
- 238000010411 cooking Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 238000011156 evaluation Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 15
- 230000003013 cytotoxicity Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 241000736199 Paeonia Species 0.000 description 11
- 235000019486 Sunflower oil Nutrition 0.000 description 11
- 239000002600 sunflower oil Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 108091006296 SLC2A1 Proteins 0.000 description 10
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 10
- 230000003285 pharmacodynamic effect Effects 0.000 description 9
- 108010087230 Sincalide Proteins 0.000 description 8
- 238000010609 cell counting kit-8 assay Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000032895 transmembrane transport Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 3
- 230000006682 Warburg effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000000961 QCM-D Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000012029 Fehling's reagent Substances 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100023537 Solute carrier family 2, facilitated glucose transporter member 2 Human genes 0.000 description 1
- 102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000008727 cellular glucose uptake Effects 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 108010070004 glucose receptor Proteins 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000003380 quartz crystal microbalance Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/65—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
- A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
Definitions
- the invention belongs to the technical field of medicine, and relates to a biologically safe anti-tumor drug sensitizer, in particular to a fluorescent carbon quantum dot, a preparation method thereof, and use in the preparation of an anti-tumor drug sensitizer.
- the fluorescent carbon quantum dots prepared by the invention have uniform size, stable and adjustable fluorescence emission, high water dispersibility, high safety and good biocompatibility, and can competitively inhibit the uptake of glucose by tumor cells and interfere with the growth of tumor cells Proliferation, increase the sensitivity of tumor cells to various anti-tumor agents, improve tumor treatment effects, and can be used for combined treatment of various tumors.
- Adjuvant first appeared in traditional Chinese medicine. Adjuvants can enhance the therapeutic effects of the monarch and minister drugs and eliminate or slow down the toxicity and potency of the monarch and minister drugs. At the same time, they play an auxiliary role in the treatment of the monarch drugs.
- the "adjuvant” concept has applications in both vaccines and chemotherapy. Studies have reported that under the combined application of vaccines and adjuvants, the body's immune response to antigens is enhanced, which improves the efficacy of vaccines, reduces the amount of antigens and the number of immunizations; anti-tumor drug sensitizers are an extension of adjuvants in tumor treatment .
- An anti-tumor drug sensitizer refers to the use of a small dose of the substance in combination with an anti-tumor drug to increase the sensitivity of tumor cells to the drug and reduce the toxic and side effects of the drug through different coordination mechanisms.
- most of the sensitizers currently used in tumor treatment are another type of preparations or traditional Chinese medicine extracts that have toxic side effects that are different from those of anti-tumor drugs, and other side effects may occur during use.
- most of the current sensitizers play a synergistic effect on specific drugs themselves, and have little effect on the development of metabolic behavior of tumor cells, and their use has limitations, that is, only work on individual drugs or cancer patients, and individual differences are large. Therefore, the development of new anti-tumor drug sensitizers that can be widely used in tumor treatment with high safety and good biocompatibility is of vital importance to tumor treatment.
- Sugar is composed of carbon, hydrogen and oxygen, which provides a carbon skeleton for the synthesis of proteins, nucleic acids and lipids and participates in cellular communication. It is the most important energy source for living organisms. For tumor cells, an adequate supply of sugar is the prerequisite for their rapid growth and proliferation and resistance to external stimuli. In recent years, the Warburg effect based on sugar and sugar metabolism has been widely concerned about the development of tumors and cancer treatment. That is, tumor cells mainly rely on glycolysis to produce energy when oxygen is sufficient. Most of the glucose absorbed by tumor cells undergoes glycolysis to produce lactic acid, and a large number of intermediate products produced during glycolysis provide a material basis for the synthesis of nucleotides, phospholipids and proteins required for the abnormal proliferation of tumor cells.
- Tumor cells have far more sugar requirements than normal cells.
- Tumor cells usually use glucose transporters (GLUT1, etc.) overexpressed on their surface to achieve their sugar uptake. Therefore, it is necessary to study how to prevent GLUT1 from mediating tumor sugar uptake to inhibit tumor cell growth or change the growth state of tumor cells to make tumors.
- GLUT1 glucose transporters
- the inventor of the present application intends to provide a biologically safe anti-tumor drug sensitizer and its preparation method and application.
- the present invention uses biologically safe raw materials to develop a simple, green and fully biocompatible
- the synthesis method prepares carbon nanodots, and further develops the biological effects of carbon dots to realize their wider biological applications.
- the purpose of the present invention is to provide a biologically safe anti-tumor drug sensitizer based on the current state of the art, in particular to a fluorescent carbon quantum dot, a preparation method thereof, and use in the preparation of an anti-tumor drug sensitizer.
- the present invention adopts biologically safe raw materials to develop a simple, green and completely biocompatible synthesis method to prepare carbon nanodots.
- the prepared fluorescent carbon quantum dots have uniform size, stable and adjustable fluorescence emission, high water dispersibility, and safety High and good biocompatibility, it can competitively inhibit the uptake of glucose by tumor cells, interfere with the growth and proliferation of tumor cells, improve the sensitivity of tumor cells to various antitumor agents, and improve the effect of tumor treatment. It can be used for various types of tumors. Combination therapy.
- the present invention uses green food processing technology, preferably a simple heating and stirring method, and uses sugar as a raw material and oil as a reaction solvent to prepare fluorescent carbon quantum dots (eCNDs).
- eCNDs fluorescent carbon quantum dots
- the fluorescent carbon quantum dot of the present invention has a particle size between 2 and 14 nm.
- the fluorescent carbon quantum dot contains four elements of C, N, O, and H, and the atomic content of C, O, and N on the surface is respectively 33% ⁇ 70at%, 28% ⁇ 35at%, 1% ⁇ 5%at.
- the mass ratio of C is 40% to 58%
- the mass ratio of H is 5% to 8%
- the mass ratio of O is 39% to 55%
- the mass ratio of N is 2% to 5 %.
- the fluorescent carbon quantum dots of the present invention have a GPC test molecular weight of 8,000 to 20,000.
- the present invention provides a simple eCNDs synthesis method, which includes the steps:
- step (2) After removing the unreacted sugar and oil solvent from the crude reaction product obtained in step (1), fluorescent carbon quantum dots (eCNDs) are obtained.
- eCNDs fluorescent carbon quantum dots
- the sugar in step (1) is edible sugar, and the oil is edible oil;
- the edible sugar includes white granulated sugar, soft white sugar, red granulated sugar, polycrystalline rock sugar, monocrystalline rock sugar, cube sugar, and borneol sugar And brown sugar;
- the edible oils include corn oil, rapeseed oil, peanut oil, hemp oil, corn oil, olive oil, camellia oil, palm oil, canola oil, sunflower oil, soybean oil, sesame oil, grape seed oil
- the round-bottomed flask in step (1) is a type commonly used in laboratories.
- the reaction temperature in step (1) is 150-199°C.
- reaction time in step (1) is 3-9 minutes.
- the mass ratio of the solvent to the reactant in step (1) is between 1:1 and 5:1.
- the method for removing unreacted sugar and oil in step (2) is selected from any one or any combination of extraction, vacuum distillation, dialysis, or high-speed centrifugation.
- the method for removing unreacted sugar and oil is extraction-assisted double-layer membrane dialysis combined with vacuum distillation, and the specific steps are as follows:
- step (1) Wash the crude reaction product obtained in step (1) several times with a mixed solution of one or more reagents such as dichloromethane, n-hexane, butyl acetate and chloroform;
- one or more reagents such as dichloromethane, n-hexane, butyl acetate and chloroform;
- step a) the crude product obtained by washing is extracted with a mixed solution of dichloromethane, n-hexane, butyl acetate or chloroform and water to obtain an aqueous solution of eCNDs;
- step c) Vacuum rotary evaporation of the eCNDs aqueous solution obtained in step b) to obtain a concentrated carbon quantum dot aqueous solution; preferably, the reaction conditions of step c) are 35-55°C water bath rotary evaporation, and the vacuum pressure is below -100KPa;
- step c) Dialysis the product obtained in step c); the dialysis conditions are: 300K/18mm and 3500K/45mm dialysis bags, the dialysis time is 48-96h, preferably, the dialysis time is 72h, and the reaction temperature is room temperature;
- the eCNDs provided by the present invention have a size distribution of 2-14 nm.
- the core has obvious carbon lattice stripes, the size of the crystalline carbon core is 2-8nm, and the hydration diameter after adding surface groups is 5-14nm. The results are shown in Figures 1 and 2.
- the zeta potential of the eCNDs provided by the present invention is -17-28mV, and the result is shown in FIG. 3.
- the eCNDs provided by the present invention contain carbon, hydrogen, oxygen and nitrogen in their skeleton, and the mass ratio of C is 40% to 58%, the mass ratio of H is 5% to 8%, and the mass ratio of O is 39% to 39%.
- the mass ratio of 55% to N is 2% to 5%.
- the atomic content of carbon, oxygen, and nitrogen on the surface are 33 to 70 at%, 28 to 35 at%, and 1 to 5 at%, respectively.
- the eCNDs provided by the present invention have a molecular weight of 8000 to 20000, and the eCNDs can be split into ion fragments with mass-to-charge ratios of 200-480, 750-920, and 1000-1600 through MALDI-TOF.
- the eCNDs provided by the present invention are irradiated with a salt concentration (K+, Na+, etc.) of 0-5Mol/L, an aqueous solution with a pH of 4-9, or strong ultraviolet light (2.5W/cm 2 ) for 0-48h, There is no obvious change in the fluorescence emission from 375 to 580 nm, and it has good fluorescence stability.
- the eCNDs provided by the present invention can perform in vivo tumor imaging in all directions and multiple angles through the excitation of different fluorescence channels.
- the fluorescence emission wavelength increases with the increase of the excitation light wavelength, and it has the properties of multicolor (blue, green, red) light emission.
- the wavelength of maximum excitation light and emission light are 440nm and 599nm respectively.
- the eCNDs when the aqueous solution concentration is less than 120 mg/mL, the eCNDs are dispersed in different media including water, phosphate buffer, cell culture fluid and fetal bovine serum. When the centrifugal speed is less than 16000 rpm and the centrifugation is within 10 minutes, There is no precipitation in the sample solution, which proves that the prepared eCNDs have good water solubility and dispersibility.
- the eCNDs provided by the present invention have good biological safety, and when the concentration is less than 4 mg/mL, the co-incubation with cells for less than 6 hours does not affect the growth and proliferation of normal cells (such as HA 1800 and MCF 10). After feeding SD rats at a dose of less than 200 mg/kg, within 12 weeks of monitoring, no inflammation and lesions occurred in all major organs and tissues (heart, liver, spleen, lung, kidney, and brain).
- Blood routine average red blood cell hemoglobin concentration (MCHC), hematocrit (HCT), red blood cell (RBC), average red blood cell volume (MCV), platelet (PLT), average red blood cell hemoglobin (MCH), white blood cell (WBC), hemoglobin ( HGB) and blood biochemical indicators: creatinine (CK), creatinine acid (Crea), urea (Urea), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), albumin (ALB), alanine aminotransferase (ALT) and total bilirubin (TBIL) are normal, consistent with the indicators of normal rats, indicating that the carbon quantum dots have high safety and biocompatibility.
- the eCNDs provided by the present invention have abundant surface functional groups such as carboxyl groups, carbonyl groups, hydroxyl groups and amino groups on the surface.
- the eCNDs provided by the present invention can be targeted and enriched at tumor sites for tumor imaging in vivo.
- the eCNDs provided by the present invention due to the presence of sugar residues on the surface, have physical and chemical properties similar to glucose, and can react with Fehling's reagent to produce brick red precipitates.
- the eCNDs provided by the present invention have sugar residues on the surface, but do not have the energy supply properties of glucose, and will not cause the increase of blood glucose concentration in the organism and the increase of animal weight.
- the eCNDs provided by the present invention due to the presence of sugar residues on the surface, are similar in structure to glucose, and can competitively bind to cell surface receptors (GLUT1, GLUT2 or GLUT4, etc.), inhibiting the uptake of glucose by tumor cells and reducing intracellular
- GLUT1, GLUT2 or GLUT4, etc. cell surface receptors
- the production of ATP reduces the body's energy supply to tumor cells, disturbs the growth and proliferation of tumor cells, thereby increasing the sensitivity of tumor cells to drugs and improving the therapeutic effect.
- the eCNDs provided by the present invention are based on the Warburg effect. By interfering with the sugar uptake of tumor cells, it affects the production of tumor cell ATP and reduces energy supply, thereby affecting the growth and proliferation of tumor cells, reducing the drug resistance of tumor cells, and improving tumors. Chemosensitivity of cells can improve the effect of chemotherapy, has broad-spectrum characteristics, can be used to prepare various anti-tumor drug sensitizers, is suitable for the sensitization of various cancer treatment methods, and improves the efficiency of tumor treatment.
- the present invention provides the application of eCNDs in tumor imaging in vivo.
- the present invention provides that eCNDs affect tumor cell proliferation, enhance the sensitivity of treatment, and the effect is more obvious when the tumor cells are starved (glucose deficiency).
- the eCNDs of the present invention can be prepared as sensitizers for clinical anti-tumor drug treatment.
- the eCNDs are used as sensitizers of anti-tumor drugs such as doxorubicin, sorafenib, temozolomide, etc., and can significantly improve the therapeutic effect of anti-tumor drugs on tumors.
- anti-tumor drugs include chemotherapy drugs and/or immunotherapy drugs and other physical therapy drugs.
- the present invention provides an anti-tumor drug composition, including an anti-tumor drug and eCNDs; the anti-tumor drug composition may also include a pharmaceutically acceptable carrier.
- the tumors include glioma, liver cancer, breast cancer, lymphoma, ovarian cancer, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, bladder cancer, thyroid cancer, prostate cancer, head and neck squamous cell carcinoma, testis At least one of cancer, gastric cancer or other solid tumors.
- the outstanding advantages and characteristics of the present invention are that edible sugar is used as a raw material, and edible oil is used as a reaction solvent, and a chemotherapeutic sensitizer fluorescent carbon quantum dots (eCNDs) are prepared through green food processing technology (simple heating and stirring).
- the preparation method of the present invention is simple, time-saving and easy to implement, low cost, can effectively avoid the addition of toxic raw materials and reagents, and has high safety.
- the prepared eCNDs have the characteristics of small particle size, good dispersion, stable fluorescence, and high safety. , ECNDs can be enriched in tumor sites through the EPR effect.
- chemotherapeutic sensitizer fluorescent carbon quantum dots are a sensitizer that broadly enhances the therapeutic effect of tumors, and can be widely applied to the combined treatment of various tumors.
- the invention provides new research concepts and ideas for tumor treatment.
- Figure 11 Dispersibility evaluation: Disperse eCNDs in different media, and observe the changes in dispersion before and after centrifugation at 16000 rpm/10 min.
- Figure 12 A fluorescence stability evaluation: the influence of salt (Na/K) on the fluorescence stability of eCNDs;
- Figure 15 Time-dependent cellular uptake of eCNDs.
- Figure 19 The results of eCNDs interfering with cell proliferation.
- Figure 20 The results of eCNDs inhibiting the glucose uptake of tumor cells.
- PET/CT imaging research results of the effect of eCNDs concentration on glucose uptake in tumor tissues.
- Figure 25 The results of the study on the effect of eCNDs on the body weight of SD rats.
- Figure 28 The pharmacodynamic evaluation of eCNDs combined with temozolomide for the treatment of glioma (eCNDs intravenously and temozolomide orally) cell apoptosis experiment results.
- Figure 29 The pharmacodynamic evaluation of eCNDs combined with temozolomide for the treatment of glioma (eCNDs intravenously and temozolomide orally) results, where A: body weight of tumor-bearing mice, B: survival curve.
- Figure 32 The effect of eCNDs on the proliferation and growth of tumors and normal cells.
- Figure 33 The effect of eCNDs on ATP production in tumor and normal cells.
- Figure 35 The results of the pharmacodynamic evaluation of eCNDs combined with sorafenib for the treatment of liver cancer (eCNDs intravenously and sorafenib orally),
- A tumor volume
- B body weight of tumor-bearing mice.
- Figure 37 The pharmacodynamic evaluation of eCNDs combined with sorafenib for the treatment of liver cancer (both eCNDs and sorafenib are administered orally),
- Figure 38 The pharmacodynamic evaluation of eCNDs combined with sorafenib for the treatment of liver cancer (both eCNDs and sorafenib are administered orally) cell apoptosis experiment results.
- Figure 39 Biological safety evaluation of eCNDs: main organ tissue sections and HE staining results.
- oil corn oil, rapeseed oil, peanut oil, hemp oil, corn oil, olive oil, camellia oil, palm oil, canola oil, sunflower oil, soybean oil, sesame oil, grape seed oil, walnut oil, and peony seed
- sugar one or more of white sugar, soft white sugar, red sugar, polycrystalline rock sugar, single crystal rock sugar, cube sugar, borneol sugar, yellow sugar, etc.
- Oil corn oil, rapeseed oil, peanut oil, hemp oil, corn oil, olive oil, camellia oil, palm oil, canola oil, sunflower oil, soybean oil, sesame oil, grape seed oil, walnut oil, and peony seed
- sugar white sugar, soft white sugar, red sugar, polycrystalline rock sugar, single crystal rock sugar, cube sugar, borneol sugar, yellow sugar, etc.
- sugar white sugar, soft white sugar, red sugar, polycrystalline rock sugar, single crystal rock sugar, cube sugar, borneol sugar, yellow sugar, etc.
- oil corn oil, rapeseed oil, peanut oil, hemp oil, corn oil, olive oil, camellia oil, palm oil, canola oil, sunflower oil, soybean oil, sesame oil, grape seed oil, walnut oil, and peony seed oil Etc.
- the resulting product is extracted, rotary steamed and dialyzed to remove residual sugar and oil to obtain eCNDs.
- sugar white sugar, soft white sugar, red sugar, polycrystalline rock sugar, single crystal rock sugar, cube sugar, borneol sugar, yellow sugar, etc.
- sugar white sugar, soft white sugar, red sugar, polycrystalline rock sugar, single crystal rock sugar, cube sugar, borneol sugar, yellow sugar, etc.
- oil corn oil, rapeseed oil, peanut oil, hemp oil, corn oil, olive oil, camellia oil, palm oil, canola oil, sunflower oil, soybean oil, sesame oil, grape seed oil, walnut oil, and peony seed oil Etc.
- oil corn oil, rapeseed oil, peanut oil, hemp oil, corn oil, olive oil, camellia oil, palm oil, canola oil, sunflower oil, soybean oil, sesame oil, grape seed oil, walnut oil, and peony seed oil Etc.
- Example 5 The eCNDs prepared in Example 5 were observed through JEM-2010 transmission electron microscope, and the results showed that the nanodots had a uniform size, as shown in FIG. 1.
- the eCNDs prepared in Example 5 were dispersed in an aqueous solution, and their particle size distribution was characterized by a dynamic light scattering method. The results showed that the prepared eCNDs had a particle size of 2-14 nm, please see FIG. 2.
- the prepared eCNDs core has obvious carbon lattice stripes, the size of the crystalline carbon core is 2-8nm, and the hydration diameter after adding surface groups is 5-14nm, as shown in Figure 1.
- Example 5 The eCNDs prepared in Example 5 were dispersed in an aqueous solution, and the zeta potential of the particle size Zeta potential meter was measured. The result showed that the zeta potential of the prepared eCNDs solution was -18 to -24 mV, as shown in FIG. 3.
- the eCNDs prepared in Example 5 were characterized by 13 C nuclear magnetic resonance, 1 H nuclear magnetic resonance and infrared spectroscopy.
- the 13 C NMR spectrum shows (as shown in Figure 4A) that the surface of the eCNDs prepared in Example 5 has sp 3 hybridized aliphatic carbon (CO, CC, and CH) signals at a chemical shift ⁇ of 0-60 ppm; eCNDs are 1
- the 1 H-NMR signal of C-OH appears at a chemical shift ⁇ of 4 to 5 ppm (as shown in Figure 4B); infrared spectroscopy is used to characterize the eCNDs prepared in Example 5, and the result is shown in Figure 4C.
- the surface of the eCNDs prepared in Example 5 may have surface functional groups such as carboxyl, carbonyl, hydroxyl, and amino groups.
- the carbon, hydrogen, oxygen, and nitrogen elements in the eCNDs prepared in Example 5 were characterized by an element analyzer.
- the results show that the framework of eCNDs provided by the present invention contains carbon, hydrogen, oxygen and nitrogen elements, and the mass ratio of C is 40.53% to 43.82%, the mass ratio of H is 5.73% to 7.94%, and the mass ratio of O is The mass ratio of 51.86% to 54.97% to N is 2.57% to 4.32%, please see attached figure 5.
- the atomic content of carbon, oxygen, and nitrogen on the surface are respectively: 60 to 70 at%, 28 to 35 at%, and 1 to 5 at%, as shown in Figure 6.
- the molecular weight of the eCNDs prepared in Example 5 was characterized by gel chromatography (GPC). As shown in Figure 7, the molecular weight of the eCNDs was 8,000 to 20,000.
- the molecular composition of the eCNDs prepared in Example 5 was characterized by MALDI TOF, and the result is shown in FIG. 8.
- the resulting spectrum of eCNDs there are molecular peaks in the m/z ranges of 200 to 480, 750 to 920, and 1000 to 1600.
- the eCNDs prepared in Example 5 were dispersed in an aqueous solution and tested by a fluorescence spectrometer. The results showed that the eCNDs aqueous solution can emit fluorescence (475 nm to 599 nm) after ultraviolet excitation (375 nm to 440 nm), and the fluorescence emission wavelength increases as the excitation wavelength increases.
- the wavelengths of the maximum excitation light and emission light are 440nm and 599nm, respectively, as shown in Figure 9.
- the eCNDs prepared in Example 5 were diluted with water in a concentration gradient, and the linear relationship between the absorbance and the concentration was investigated by an ultraviolet spectrophotometer (270nm). The results showed that the eCNDs in the concentration range of 25 ⁇ 300 ⁇ g/mL and its corresponding absorbance had good linearity. , Can be used for quantitative analysis of related eCNDs, as shown in Figure 10.
- the eCNDs prepared in Example 5 were dispersed in different media including water, phosphate buffer, cell culture medium and fetal calf serum. The dispersion of the carbon quantum dot solution before and after centrifugation was observed. No obvious precipitation was observed in the media, and the color of the solution did not change significantly, indicating that the prepared eCNDs have good dispersibility in different media, as shown in Figure 11.
- the eCNDs prepared in Example 5 were respectively exposed to ultraviolet light environment (2.5W/cm 2 , irradiation 0 ⁇ 48h), dispersed in different concentrations of salt (K+, Na+, etc., 0 ⁇ 5Mol/L) aqueous solution and pH (4 ⁇ 4 ⁇ 9)
- the fluorescence stability was investigated, and the results showed that the fluorescence characteristics of 375 ⁇ 580nm did not change significantly under the interference of ultraviolet light, NaCl and pH, and it had good fluorescence stability, as shown in Figure 12A. , B and C are shown.
- the eCNDs prepared in Example 5 were added to the culture medium of tumor cells (U87 and HepG2) and normal cells (1800 and HL 7702) at different concentrations, and incubated with a cell incubator for 6 hours.
- the cells of eCNDs were investigated by CCK-8 toxicity. The results show that eCNDs have low cytotoxicity and high safety, as shown in Figure 13.
- the eCNDs prepared in Example 5 were added to the U87 cell culture medium at different concentrations.
- the cell uptake was investigated after incubation for 1 h. The results showed that the cell uptake of eCND was concentration-dependent. The better cellular uptake is shown in Figure 14.
- the eCNDs prepared in Example 5 were added to the U87 cell culture medium at 200 ⁇ g/mL, and their cell uptake was investigated at different time periods. The results showed that the cell uptake of eCND is time-dependent, and eCND has the best 2h Cell uptake, as shown in Figure 15.
- eCNDs prepared in Example 5 were co-incubated with different inhibitors to study the transmembrane transport mechanism of chemotherapeutic sensitizers.
- the results show that eCND is mainly transported across the cell membrane through the glucose receptor GLUT1 in the form of passive transport, as shown in Figure 16.
- Example 5 After the eCNDs prepared in Example 5 were incubated with U 87 cells, the cells were labeled with GLUT-1 fluorescent probe (TRITC-labeled GLUT1 probe), and the fluorescence distribution of eCNDs and GLUT-1 was observed under a confocal microscope . The results showed that the fluorescence of eCNDs mostly overlapped with the fluorescence of GLUT-1, which proved the mechanism of eCNDs transmembrane transport through GLUT1, as shown in Figure 17.
- GLUT-1 fluorescent probe TRITC-labeled GLUT1 probe
- the eCNDs (200 ⁇ g/mL) prepared in Example 5 were added to the U87 cell and 1800 cell culture medium and incubated with the cells.
- the quartz crystal microbalance (QCM-D) was used to determine the frequency ( ⁇ f) and dissipation value of the quartz crystal.
- ( ⁇ D) is an evaluation index to study the interaction between eCNDs and cells. The results showed that compared with normal cells, eCNDs are more likely to be adsorbed on the surface of tumor cells with high GLUT-1 expression, as shown in Figure 18.
- the eCNDs (200 ⁇ g/mL) prepared in Example 5 were added to the cell culture medium and incubated with the cells (U87 and 1800) for 12 hours, then the medium was changed to a sugar-free medium and incubated for another 12 hours, and then changed back to containing eCNDs (200 ⁇ g/mL) culture medium to continue to incubate the cells.
- the cell viability real-time monitoring system the state of the cells is monitored. The results show that compared with normal cells, eCNDs can significantly inhibit the growth and proliferation of tumor cells, as shown in Figure 19.
- the eCNDs prepared in Example 5 were added to the culture dishes of U87 cells at different concentrations (100, 200, and 400 ⁇ g/mL). After 30 minutes, glucose fluorescent probes were added to observe the glucose uptake of the cells. The results show that eCNDs can inhibit the uptake of glucose by cells, and the inhibition is proportional to its concentration, as shown in Figure 20.
- the eCNDs prepared in Example 5 were intravenously injected into mice bearing glioma in situ. At different time periods, the fluorescence distribution in vivo was observed by a small animal in vivo imaging instrument, indicating that fluorescent carbon quantum dots can accumulate in the brain through the EPR effect Perform intravital imaging of the glioma site, as shown in Figure 21.
- the eCNDs prepared in Example 5 were injected into mice with in situ brain glia at different concentrations via the tail vein, and the glucose content at the tumor site was monitored by PET/CT.
- the results show that eCNDs can effectively inhibit the glucose uptake of tumor cells, and the effect is most obvious when the concentration of eCNDs is 2 mg and intravenous injection for 30 minutes, as shown in Figure 22.
- the eCNDs and glucose prepared in Example 5 were characterized by 1 H nuclear magnetic resonance method and infrared spectroscopy, respectively, and the structural characteristics were analyzed.
- the result is shown in Figure 23, which shows that the chemical shift ⁇ of eCNDs is 2.7 ⁇ 3.7ppm, 4.2 ⁇ 4.8 ppm, glucose has a similar C 2-6 -H and C 1 H-NMR signals of 1-6 -OH;
- IR spectra show, eCNDs in 3500 ⁇ 3700cm -1, 2850 ⁇ 2960cm -1, 1710 ⁇ 1750cm - 1.
- the analysis of the above experimental results can indicate that there may be functional groups similar to the glucose surface groups on the surface of eCNDs.
- the eCNDs and glucose prepared in Example 5 were respectively orally administered to SD rats (both doses are 200 mg/kg), and the trend of changes in the blood glucose concentration of the rats was monitored.
- the phenomenon of large fluctuations in a short period of time, eCNDs has no effect on the blood glucose concentration of rats, indicating that eCNDs may not have the characteristics of glucose supply.
- the eCNDs prepared in Example 5 were orally administered to SD rats (200 mg/kg), and fasted rats were used as negative controls. Rats that had eaten normal food and edible sugar (200 mg/kg) were used as negative controls. Monitor the change trend of rat body weight to study the biological characteristics of eCNDs. The results showed that compared with the rats that were eating and sugar, the weight change trend of the rats that consumed eCNDs was consistent with that of fasted rats, indicating that eCNDs could not provide energy for the body, as shown in Figure 25.
- eCNDs prepared in Example 5 were added to U87 cell culture dishes at different concentrations and (or) 20 ⁇ g/mL temozolomide, and the cytotoxicity was evaluated by CCK-8. The results are shown in Figure 26, eCNDs significantly improved the cytotoxicity of temozolomide.
- eCNDs prepared in Example 5 were added to U87 cell culture dishes at different concentrations and (or) 20 ⁇ g/mL temozolomide, and the cytotoxicity was evaluated by LIVEDEAD. The results are shown in Figure 27, eCNDs significantly increased the cytotoxicity of temozolomide.
- the eCNDs prepared in Example 5 were administered intravenously to mice bearing glioma in situ, and temozolomide was administered orally. The vital signs and life cycle of the mice were tested. The results showed that the combined application of eCNDs and temozolomide killed Glioma cells (as shown in Figure 28) improve the quality of life of tumor-bearing mice (as shown in Figure 29A) and life cycle (as shown in Figure 29B).
- the eCNDs prepared in Example 5 were added to Hep G2, MCF-7, A549, H1299, HCT 116, 4T1 and PANC-1 cell culture dishes at a concentration of 200 ⁇ g/mL and/or 20 ⁇ g/mL DOX, respectively.
- CCK-8 was evaluated for cytotoxicity. As shown in Figure 30, eCNDs significantly improved the cytotoxicity of DOX.
- the eCNDs prepared in Example 5 were added to the cell culture dishes of MCF-7 and MCF-10 at a concentration of 200 ⁇ g/mL and/or 20 ⁇ g/mL DOX, respectively, and the cytotoxicity was evaluated by CCK-8. The results are shown in Figure 31, eCNDs significantly increased the toxicity of DOX to tumor cells.
- the eCNDs prepared in Example 5 were added to the cell culture dishes of Hep G2 and HL 7702 at different concentrations, and the cytotoxicity was evaluated by CCK-8. The results are shown in Figure 32. Compared with normal cells, eCNDs significantly inhibited the growth and proliferation of tumor cells under long-term intervention.
- the eCNDs prepared in Example 5 were added to the cell culture dishes of Hep G2 and HL 7702 at different concentrations, respectively, and the ATP content in the cells was evaluated by the ATP fluorescent probe. The results are shown in Figure 33. Compared with normal cells, eCNDs significantly inhibited tumor cell ATP production.
- ECNDs 5 prepared in Example sorafenib administered in a concentration of 400 ⁇ g / mL with various concentrations of Hep G2 cells to the petri dish, the value of IC 50 was calculated for 24 hours were evaluated. The results are shown in Figure 34, eCNDs significantly increased the cytotoxicity of sorafenib.
- eCNDs prepared in Example 5 and sorafenib were used in combination with different treatment schemes in mice with liver cancer subcutaneous tumors, through changes in tumor volume, body weight, and cell apoptosis.
- the pharmacodynamic evaluation was carried out in the death experiment. The results are shown in Figures 35A and B, 36, sorafenib combined with eCNDs treatment significantly inhibited tumor growth.
- Example 5 After the eCNDs prepared in Example 5 were fed SD at a dose of less than 200 mg/kg for 12 weeks, their main organs were stained for biochemical tissue sections, as shown in Figure 39, their blood routine and blood biochemical indicators were tested to investigate their biological safety sex. The results are shown in Figure 40. There were no inflammatory lesions in all organs of SD rats that consumed eCNDs. The blood routine and blood biochemical indexes were normal, which were consistent with those of normal rats, indicating that the carbon quantum dots have high safety and biological characteristics. compatibility.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Optics & Photonics (AREA)
- Manufacturing & Machinery (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (24)
- 一种荧光碳量子点,其特征在于,其粒径在2~14nm之间,所述的荧光碳量子点包含C、N、O、H四种元素,其表面的C、O、N的原子含量分别为33%~70at%,28%~35at%,1%~5%at。
- 根据权利要求1所述的荧光碳量子点,其特征在于,C的质量比为40%~58%,H的质量比为5%~8%,O的质量比为39%~55%和N的质量比为2%~5%。
- 根据权利要求1所述的荧光碳量子点,其特征在于,所述荧光碳量子点的GPC测试分子量为8000~20000。
- 根据权利要求1所述的荧光碳量子点,其特征在于,所述荧光碳量子点在3500~3700cm -1、2850~2960cm -1、1710~1750cm -1、1660~1700cm -1、1507cm -1、1250~1300cm -1、1100~1200cm -1处分别具有v(O-H)、v(C-H)、v(C=O)、v(C-C)、v(C-H)、v(C-N)和v(C-O)特征红外吸收峰,且在化学位移δ为0~60ppm出现sp3杂化的 13C(C-O,C-C,C-N)NMR信号,以及在化学位移δ为4~5ppm出现C-OH的 1H-NMR信号。
- 根据权利要求1-4所述的荧光碳量子点的制备方法,其特征在于,其包括步骤,(1)以糖为原料、油为反应溶剂,通过加热搅拌得到粗产物;(2)去除粗产物中的糖和油。
- 根据权利要求5所述的制备方法,其特征在于,所述步骤(1)中油与糖的质量比为1:1~5:1。
- 根据权利要求5所述的制备方法,其特征在于,所述步骤(1)中糖为可食用糖,油为可食用油。
- 根据权利要求7所述的制备方法,其特征在于,所述可食用糖选自白砂糖、绵白糖、赤砂糖、多晶体冰糖、单晶体冰糖、方糖、冰片糖以及黄砂糖中的一种或者几种。
- 根据权利要求7所述的制备方法,其特征在于,所述可食用油选自粟米油、菜籽油、花生油、火麻油、玉米油、橄榄油、山茶油、棕榈油、芥花子油、葵花子油、大豆油、芝麻油、葡萄籽油、核桃油和牡丹籽油中的一种或者几种。
- 根据权利要求5所述的荧光碳量子点的一种制备方法,其特征在于,所述步骤(1)中的反应温度为150~199℃,反应时间为3~9min。
- 根据权利要求5所述的制备方法,其特征在于,所述步骤(2)中的去除粗产物中的糖和油的方法选自萃取、减压蒸馏、透析或高速离心中的任一种或其任意组合。
- 根据权利要求5或11所述的制备方法,其特征在于,所述步骤(2)中的去除粗产物中的 糖和油的方法为萃取辅助的双层膜透析联合减压蒸馏。
- 根据权利要求12所述的制备方法,其特征在于,所述萃取辅助的双层膜透析联合减压蒸馏的步骤如下:a)洗涤步骤(1)中得到的反应粗产物若干次;b)将步骤a)洗涤所得粗产物进行萃取,得到荧光碳量子点水溶液;c)将步骤b)所得的荧光碳量子点水溶液经真空旋蒸得到浓缩的荧光碳量子点水溶液;d)将步骤c)所得产物进行透析;e)得到所述的荧光碳量子点。
- 根据权利要求13所述的制备方法,其特征在于,所述步骤a)中的洗涤剂为为二氯甲烷、正己烷、乙酸丁酯和三氯甲烷中的一种或几种试剂的混合。
- 根据权利要求13所述的制备方法,其特征在于,所述步骤b)中的萃取剂为二氯甲烷、正己烷、乙酸丁酯和三氯甲烷与水的混合溶液。
- 根据权利要求13所述的制备方法,其特征在于,所述步骤c)中的真空旋蒸为35~55℃水浴旋蒸,真空压为-100KPa以下。
- 根据权利要求13所述的制备方法,其特征在于,所述步骤d)中的透析时长为48-96h。
- 权利要求1-4所述的荧光碳量子点在制备肿瘤体内成像制剂中的应用。
- 权利要求1-4所述的荧光碳量子点在制备抗肿瘤药物的增敏剂中的用途。
- 根据权利要求19所述的用途,其特征在于,所述抗肿瘤药物包括化疗药物和/或免疫治疗药物及其它物理治疗药物。
- 根据权利要求20所述的用途,其特征在于,所述化疗药物选自多柔比星、索拉菲尼或替莫唑胺。
- 根据权利要求19-21所述的用途,其特征在于,所述肿瘤包括神经胶质瘤、肝癌、乳腺癌、淋巴瘤、卵巢癌、软组织肉瘤、成骨肉瘤、横纹肌肉瘤、膀胱癌、甲状腺癌、前列腺癌、头颈部鳞癌、睾丸癌或胃癌。
- 一种抗肿瘤药物组合物,其特征在于,包括权利要求1~4所述的荧光碳量子点和抗肿瘤药物。
- 根据权利要求23所述的抗肿瘤药物组合物,其特征在于,所述抗肿瘤药物组合物还包含药学上可接受的载体。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010129354 | 2020-02-28 | ||
CN202010129354.1 | 2020-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021169744A1 true WO2021169744A1 (zh) | 2021-09-02 |
Family
ID=77413389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/074781 WO2021169744A1 (zh) | 2020-02-28 | 2021-02-02 | 一种荧光碳量子点及其制备方法和在制备抗肿瘤药物增敏剂中的用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113322065B (zh) |
WO (1) | WO2021169744A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115124998A (zh) * | 2022-07-06 | 2022-09-30 | 山东大学 | 一种n、s、b掺杂的中草药药渣碳点、荧光探针及应用 |
CN116103041A (zh) * | 2023-01-19 | 2023-05-12 | 河南大学 | 一种以药物功能保留策略合成的碳点及其制备方法和应用 |
CN116200192A (zh) * | 2023-02-21 | 2023-06-02 | 广东工业大学 | 一种同位素标记的碳量子点及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105727313A (zh) * | 2014-12-12 | 2016-07-06 | 中国科学院大连化学物理研究所 | 一种来自啤酒的碳点的制备方法及应用 |
CN107115319A (zh) * | 2017-04-05 | 2017-09-01 | 汪涛 | 一种生物安全性碳量子点负载阿霉素复合体及其制备方法和应用 |
CN107381536A (zh) * | 2017-06-08 | 2017-11-24 | 四川大学 | 一种快速、大批量制备水溶性荧光碳量子点的方法 |
CN108837156A (zh) * | 2018-06-21 | 2018-11-20 | 河北师范大学 | 一种碳点载药体系的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103980894B (zh) * | 2014-05-30 | 2015-09-09 | 吉林大学 | 一种对癌细胞具有靶向识别功能的荧光碳量子点、制备方法及其应用 |
CN106957050A (zh) * | 2017-03-17 | 2017-07-18 | 山西大学 | 一种荧光碳量子点及其制备方法和应用 |
CN109207147B (zh) * | 2017-07-05 | 2021-06-29 | 复旦大学 | 一种具有荧光、光声、光热效应的碳纳米点及其合成方法 |
-
2020
- 2020-06-25 CN CN202010595729.3A patent/CN113322065B/zh active Active
-
2021
- 2021-02-02 WO PCT/CN2021/074781 patent/WO2021169744A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105727313A (zh) * | 2014-12-12 | 2016-07-06 | 中国科学院大连化学物理研究所 | 一种来自啤酒的碳点的制备方法及应用 |
CN107115319A (zh) * | 2017-04-05 | 2017-09-01 | 汪涛 | 一种生物安全性碳量子点负载阿霉素复合体及其制备方法和应用 |
CN107381536A (zh) * | 2017-06-08 | 2017-11-24 | 四川大学 | 一种快速、大批量制备水溶性荧光碳量子点的方法 |
CN108837156A (zh) * | 2018-06-21 | 2018-11-20 | 河北师范大学 | 一种碳点载药体系的制备方法 |
Non-Patent Citations (3)
Title |
---|
CAILOTTO SIMONE, AMADIO EMANUELE, FACCHIN MANUELA, SELVA MAURIZIO, PONTOGLIO ENRICO, RIZZOLIO FLAVIO, RIELLO PIETRO, TOFFOLI GIUSE: "Carbon Dots from Sugars and Ascorbic Acid: Role of the Precursors on Morphology, Properties, Toxicity, and Drug Uptake", ACS MEDICINAL CHEMISTRY LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 9, no. 8, 9 August 2018 (2018-08-09), US, pages 832 - 837, XP055840554, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.8b00240 * |
LIU XIAOXIA; YANG CHUNLAN; ZHENG BAOZHAN; DAI JIANYUAN; YAN LEI; ZHUANG ZHENJING; DU JUAN; GUO YONG; XIAO DAN: "Green anhydrous synthesis of hydrophilic carbon dots on large-scale and their application for broad fluorescent pH sensing", SENSORS AND ACTUATORS B: CHEMICAL, ELSEVIER BV, NL, vol. 255, 18 August 2017 (2017-08-18), NL, pages 572 - 579, XP085229021, ISSN: 0925-4005, DOI: 10.1016/j.snb.2017.08.101 * |
YANG, KUN ., WANG CHUNLAI ,DING SHENG,LIU CHANGJUN ,TIAN FENG ,LI FAN: "A State-of-the-art Review on Fluorescent Carbon Quantum Dots2 Fabrication Characterization and Potential in Cancer Therapy", MATERIALS REVIEW, vol. 33, no. 5, 10 May 2019 (2019-05-10), pages 1475 - 1482, XP055840552 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115124998A (zh) * | 2022-07-06 | 2022-09-30 | 山东大学 | 一种n、s、b掺杂的中草药药渣碳点、荧光探针及应用 |
CN116103041A (zh) * | 2023-01-19 | 2023-05-12 | 河南大学 | 一种以药物功能保留策略合成的碳点及其制备方法和应用 |
CN116103041B (zh) * | 2023-01-19 | 2024-01-19 | 河南大学 | 一种以药物功能保留策略合成的碳点及其制备方法和应用 |
CN116200192A (zh) * | 2023-02-21 | 2023-06-02 | 广东工业大学 | 一种同位素标记的碳量子点及其制备方法 |
CN116200192B (zh) * | 2023-02-21 | 2024-03-08 | 广东工业大学 | 一种同位素标记的碳量子点及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113322065B (zh) | 2023-07-25 |
CN113322065A (zh) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021169744A1 (zh) | 一种荧光碳量子点及其制备方法和在制备抗肿瘤药物增敏剂中的用途 | |
CN103221040B (zh) | 双硫仑制剂及用途 | |
CN107812008B (zh) | 一种近红外荧光成像小分子抗癌纳米药物的制备方法 | |
CN104306333B (zh) | 一种卡巴他赛脂质微球注射液及其制备方法 | |
CN110151776A (zh) | 一种双功能核苷水凝胶及其制备方法和用途 | |
CN114177306B (zh) | 一种iNGR/R9双重修饰的阿霉素靶向脂质体及抗肿瘤活性评价 | |
CN106749343B (zh) | 一种酰腙席夫碱铜配合物-人血清白蛋白复合物及其应用 | |
CN109999197A (zh) | 肿瘤靶向的纳米复合物、制备方法及其在声动力介导的肿瘤精准治疗中的应用 | |
CN1935812B (zh) | 金属富勒醇及其在制备抑制肿瘤生长药物中的应用 | |
CN101695502B (zh) | 镧富勒醇及其在制备抑制肿瘤生长药物中的应用 | |
CN101402667A (zh) | 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途 | |
JP2019508388A (ja) | 骨髄抑制を治療するための薬物の製造におけるフラーレン/金属フラーレンの使用 | |
WO2023245857A1 (zh) | 一种辣椒素衍生化光敏剂及其制备方法与应用 | |
CN107243000B (zh) | 载药杂化纳米粒子及其制备方法 | |
CN105770912A (zh) | 具有肿瘤近红外荧光显像功能的载药atp敏感脂质体及其制备方法 | |
CN115192708A (zh) | 负载抗肿瘤药物的纳米复合材料、纳米载药体系及制备与应用 | |
CN105476956B (zh) | 一种抑制脑癌的藻蓝蛋白-聚乳酸-阿霉素胶束及其制备方法和应用 | |
CN113845904B (zh) | 硼氮掺杂石墨烯量子点的制备及其在硼中子俘获治疗药物中的应用 | |
CN111265482A (zh) | 一种甘草次酸和/或叶酸配基修饰的斑蝥素固体脂质纳米粒和制备方法 | |
CN110078770A (zh) | 一种具有喹啉酮四价铂结构的化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN111087376B (zh) | 一种钆掺杂孟加拉玫瑰纳米点及其制备方法和应用 | |
CN115947745B (zh) | 一种基于白蛋白的光热转换纳米材料及其制备方法和应用 | |
CN111701026B (zh) | 抗肿瘤的组合药物纳米载体及其制备方法 | |
CN113975247B (zh) | 一种包封dl-薄荷醇和双氯芬酸的plga纳米粒子及其制备方法与应用 | |
CN113274398B (zh) | 一种抑制肿瘤细胞糖代谢的纳米自组装材料及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21761376 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21761376 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31/03/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21761376 Country of ref document: EP Kind code of ref document: A1 |